Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Plus Therapeutics
PSTV
Plus Therapeutics
Regulatory Hurdles And Funding Risks Will Hamper CNS Pipeline Temporarily
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
20 Aug 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
83.8% undervalued
intrinsic discount
20 Aug
US$0.49
Loading
1Y
-66.4%
7D
-22.6%
Author's Valuation
US$3.0
83.8% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
83.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-42m
42m
2014
2017
2020
2023
2025
2026
2028
Revenue US$42.2m
Earnings US$7.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
65.12%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$7.23m
Earnings '28
x
110.17x
PE Ratio '28
=
US$796.50m
Market Cap '28
US$796.50m
Market Cap '28
/
218.08m
No. shares '28
=
US$3.65
Share Price '28
US$3.65
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$3.00
Fair Value '25
